{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:32:09Z","timestamp":1789421529476,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007380","name":"Fondation de l'Avenir pour la Recherche M\u00e9dicale Appliqu\u00e9e","doi-asserted-by":"publisher","award":["2018-AP-RM-18-030"],"award-info":[{"award-number":["2018-AP-RM-18-030"]}],"id":[{"id":"10.13039\/100007380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07728-8","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:00:35Z","timestamp":1767661235000},"page":"3291-3296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["First-line [18F]F-choline PET\/CT in primary hyperparathyroidism: a cost-effectiveness study from the diagnostic randomized APACH2 trial"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-9899","authenticated-orcid":false,"given":"Elske","family":"Quak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Lasne-Cardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Cavarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Jegoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Guery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Grellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Nadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Berchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"7728_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2024.1421","author":"E Quak","year":"2024","unstructured":"Quak E, Lasne-Cardon A, Cavarec M, Lireux B, Bastit V, Roudaut N, et al. F18-choline PET\/CT or MIBI SPECT\/CT in the surgical management of primary hyperparathyroidism: a diagnostic randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2024. https:\/\/doi.org\/10.1001\/jamaoto.2024.1421.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"7728_CR2","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1007\/s00259-024-06771-1","volume":"51","author":"S van Mossel","year":"2024","unstructured":"van Mossel S, Saing S, Appelman-Dijkstra N, Quak E, Schepers A, Smit F, et al. Cost-effectiveness of one-stop-shop [18F]fluorocholine PET\/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2024;51:3585\u201395. https:\/\/doi.org\/10.1007\/s00259-024-06771-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7728_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.surg.2021.03.075","volume":"171","author":"A Yap","year":"2022","unstructured":"Yap A, Hope TA, Graves CE, Kluijfhout W, Shen WT, Gosnell JE, et al. A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. Surgery. 2022;171:55\u201362. https:\/\/doi.org\/10.1016\/j.surg.2021.03.075.","journal-title":"Surgery"},{"key":"7728_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12902-020-00667-5","volume":"21","author":"E Quak","year":"2021","unstructured":"Quak E, Lasne Cardon A, Ciappuccini R, Lasnon C, Bastit V, Le Henaff V, et al. Upfront F18-choline PET\/CT versus Tc99m-sestaMIBI SPECT\/CT guided surgery in primary hyperparathyroidism: the randomized phase III diagnostic trial APACH2. BMC Endocr Disord. 2021;21:3. https:\/\/doi.org\/10.1186\/s12902-020-00667-5.","journal-title":"BMC Endocr Disord"},{"key":"7728_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1088\/1361-6498\/aaa86f","volume":"38","author":"S Rep","year":"2018","unstructured":"Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L. 18F-choline PET\/CT for parathyroid scintigraphy: significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. J Radiol Prot. 2018;38:343\u201356. https:\/\/doi.org\/10.1088\/1361-6498\/aaa86f.","journal-title":"J Radiol Prot"},{"key":"7728_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s1386-5056(03)00044-3","volume":"70","author":"FH Roger France","year":"2003","unstructured":"Roger France FH. Case mix use in 25 countries: a migration success but international comparisons failure. Int J Med Inform. 2003;70:215\u20139. https:\/\/doi.org\/10.1016\/s1386-5056(03)00044-3.","journal-title":"Int J Med Inform"},{"key":"7728_CR7","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.2967\/jnumed.120.245993","volume":"62","author":"E Hindi\u00e9","year":"2021","unstructured":"Hindi\u00e9 E, Schwartz P, Avram AM, Imperiale A, Sebag F, Ta\u00efeb D. Primary hyperparathyroidism: defining the appropriate preoperative imaging algorithm. J Nucl Med. 2021;62:3S-12S. https:\/\/doi.org\/10.2967\/jnumed.120.245993.","journal-title":"J Nucl Med"},{"key":"7728_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-020-02487-y","volume":"71","author":"L Giovanella","year":"2021","unstructured":"Giovanella L, Bacigalupo L, Treglia G, Piccardo A. Will 18F-fluorocholine PET\/CT replace other methods of preoperative parathyroid imaging? Endocrine. 2021;71:285\u201397. https:\/\/doi.org\/10.1007\/s12020-020-02487-y.","journal-title":"Endocrine"},{"key":"7728_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.760419","volume":"12","author":"MA Morris","year":"2021","unstructured":"Morris MA, Saboury B, Ahlman M, Malayeri AA, Jones EC, Chen CC, et al. Parathyroid imaging: past, present, and future. Front Endocrinol (Lausanne). 2021;12:760419. https:\/\/doi.org\/10.3389\/fendo.2021.760419.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7728_CR10","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s00259-021-05334-y","volume":"48","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2021","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, Giovanella L, Carri\u00f3 Gasset I, Hindi\u00e9 E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021;48:2801\u201322. https:\/\/doi.org\/10.1007\/s00259-021-05334-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7728_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-018-4123-z","volume":"46","author":"G Treglia","year":"2019","unstructured":"Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:751\u201365. https:\/\/doi.org\/10.1007\/s00259-018-4123-z.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07728-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:22Z","timestamp":1774401982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07728-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7728"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07728-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The APACH2 trial was approved by the\n                      Local Medical Ethics Committee\n                      South-East II in July 2019 (Reference 2019\u201335, N\u00b0 EudraCT: 2019\u2013000274-36) and by the French Agency for Medical and Health products Safety (Reference: MEDAECNAT-2019\u201304-00001_2019-000274\u201336) in May 2019. The trial protocol was performed in accordance with the ethical standards of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients gave written informed consent before study entry and any study procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that they have no conflict of interest in relation to this work.Dr Quak has received speaker and consultant honoraria from Adacap and Curium Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/Disclosure"}}]}}